Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL20495605 | 1.00 | ACHE (0.40) | ACHEKCNH2KDM4EMEN1USP2 | |
| SCHEMBL16470534 | 0.86 | KMT2A (0.43) | ACHEKDM4EMEN1USP2ALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL30661306 | 0.83 | ACHE (0.51) | ACHEKCNH2 | |
| Trifluoromethanesulfonic Acid SCHEMBL4485013 | 0.76 | KCNH2 (0.40) | ACHEKCNH2KDM4EALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL4881196 | 0.76 | KDM4E (0.47) | ACHEKCNH2KDM4EALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL2996949 | 0.76 | ACHE (0.42) | ACHEKCNH2 | |
| Trifluoromethanesulfonic Acid SCHEMBL31472680 | 0.75 | KCNH2 (0.41) | ACHEKCNH2KDM4EALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL4497025 | 0.75 | KCNH2 (0.41) | ACHEKCNH2KDM4EALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL3855070 | 0.74 | KCNH2 (0.43) | ACHEKCNH2 | |
| Trifluoromethanesulfonic Acid SCHEMBL6439196 | 0.74 | ACHE (0.43) | ACHEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | CBR1, POR, CAT | ACHE 941/4885KCNH2 1920/4885KDM4E 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.